These cookies do not store any personal information.Ĭookielawinfo-checkbox-advertising-targeting This category only includes cookies that ensures basic functionalities and security features of the website. He served in a range of executive management positions at Novartis, including global Head of Corporate Strategy and Country President for the Pharma Business in Australia.įor more information about Merck, please visit Necessary cookies are absolutely essential for the website to function properly. Prior to that, Udit Batra worked at Novartis Vaccines and Diagnostics, where he was head of Global Public Health and Market Access. Udit Batra joined Merck in 2011 to head the Group’s Consumer Health business. If approved, the acquisition will be the largest in Merck’s almost 350-year history and marks an inflection point for both companies as it will deliver significant customer benefits, including a broader, complementary range of products and capabilities, greater investment in breakthrough innovations, enhanced customer service and a leading e-commerce and distribution platform in the $130 billion global life science industry. life science company Sigma-Aldrich as part of its “Fit for 2018” transformation and growth strategy aimed at building three strong platforms for sustainable, profitable growth. Merck, in September 2014, announced the planned acquisition of U.S. Merck’s planned acquisition of Sigma-Aldrich is the largest in the Company’s 350-year history I also want to express my gratitude to the Sigma-Aldrich employees for building the organization into a leading global life science tools company and to Rakesh, personally, for providing excellent leadership to the Sigma-Aldrich organization, both culturally and as demonstrated by the company’s strong performance.” “Udit is a proven leader who has demonstrated his ability to work successfully with his leadership team to guide large organizations, drive performance and deliver to our customers. “Today’s appointment marks another important step in the acquisition of Sigma-Aldrich as it provides stable and strong leadership and continued customer focus during the crucial months of integration planning and beyond,” said Karl-Ludwig Kley, Chairman of the Executive Board of Merck. Rakesh Sachdev will serve in an advisory capacity, as needed, to ensure a smooth transition. Until then, Merck Millipore and Sigma-Aldrich will continue to operate as separate companies with Udit Batra and Rakesh Sachdev, President and CEO of Sigma-Aldrich, running both organizations independently. The planned $ 17 billion transaction remains subject to customary closing conditions and regulatory approvals, which the company expects to have completed in mid-2015.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |